Hackensack, United States
Champions Oncology, Inc., established in 2007, is a US-based biotech firm specializing in oncology-focused Contract Research Organization (CRO) services. The company's tagline, "US-based, End-to-End Oncology Pharmacology Solutions CRO", underscores its comprehensive suite of offerings that enhance the efficiency of oncology drug development.
The cornerstone of their service is the Champions TumorGraft® (CTG) platform, a robust collection of Patient-Derived Xenograft (PDX) models mirroring human tumor biology closely. This platform allows for realistic evaluation of drug response, biomarker discovery, and testing of novel drug combinations. Their collaboration network with top-tier oncology institutions facilitates the procurement of these models.
In March 2015, the company secured a $14.00M Post-IPO Equity investment, backed by investors including New Enterprise Associates, Battery Ventures, Perceptive Advisors, Sabby Capital, and Dan Mendelson. Positioned at the intersection of Biotechnology and Health Care, Champions Oncology is well-suited to drive innovation in personalized cancer therapies.
